High Mobility Group Box–1 as a Therapeutic Target Downstream of Tumor Necrosis Factor
Open Access
- 15 June 2003
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 187 (s2), S391-S396
- https://doi.org/10.1086/374753
Abstract
The discovery of tumor necrosis factor (TNF) as a necessary and sufficient mediator of systemic inflammation started a new field of research to rationally modulate cytokine responses to therapeutic advantage. However, the early kinetics of the TNF response during infection defined an extremely narrow window of opportunity during which anti-TNF therapeutics are efficacious, hampering clinical development for severe sepsis. Because death from severe sepsis often occurs as a late phenomenon, we began a search began for putative “late” mediators that could be targeted after the onset of infection. We have now identified high mobility group box—1 (HMGB1) as a late mediator of endotoxemia and sepsis. HMGB1 is released by activated macrophages, induces the release of other proinflammatory mediators, and mediates lethality when overexpressed. Administration of anti-HMGB1 antibodies inhibit systemic inflammation, even in established cases, because HMGB1 activity is elevated at significantly later time points than TNF or interleukin-1. It will now be important to determine whether this wider window of activity can be translated into therapeutic advantage for human inflammatory disease.Keywords
This publication has 44 references indexed in Scilit:
- High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitisArthritis & Rheumatism, 2002
- Release of chromatin protein HMGB1 by necrotic cells triggers inflammationNature, 2002
- Stimulation of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for advanced glycation end-productsBiochemical Journal, 2002
- The Significance of Changes in High Mobility Group-1 Protein mRNA Expression in Rats After Thermal InjuryShock, 2002
- Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiationBiochemical Journal, 2001
- Dual roles for HMGB1: DNA binding and cytokineInnate Immunity, 2001
- Antibodies against A peptide sequence located in the linker region of the HMG‐1/2 box domains in sera from patients with juvenile rheumatoid arthritisArthritis & Rheumatism, 1997
- Antibodies to Hmg Proteins in Patients with Drug‐Induced AutoimmunityArthritis & Rheumatism, 1994
- Expression of P30, a protein with adhesive properties, in Schwann cells and neurons of the developing and regenerating peripheral nerve.The Journal of cell biology, 1991
- Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemiaNature, 1987